Trial Profile
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CONSONANCE
- Sponsors Roche
- 13 Sep 2023 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 12 Aug 2023 This trial has been completed in Hungary.
- 26 Oct 2022 Status changed from recruiting to active, no longer recruiting.